BiotechTube

Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis Vulgaris

Conditions

Psoriasis Vulgaris

Trial Timeline

Oct 31, 2018 → Mar 17, 2020

NCT ID
NCT03731091

About Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)

Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.) is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Psoriasis Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT03731091. Target conditions include Psoriasis Vulgaris.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03731091Phase 3Completed

Competing Products

20 competing products in Psoriasis Vulgaris

See all competitors
ProductCompanyStageHype Score
Ixekizumab + PlaceboEli LillyPhase 2
52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
52
IxekizumabEli LillyPhase 3
77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
77
Placebo + BaricitinibEli LillyPhase 2
52
CT-P43 + StelaraCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
AMG 139AstraZenecaPhase 1
33
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77
alefaceptAstellas PharmaPhase 3
77
peficitinib + PlaceboAstellas PharmaPhase 2
52
AlefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
ASKP1240 + PlaceboAstellas PharmaPhase 2
52

Other Products from Glenmark Pharmaceuticals

Nitric OxidePhase 3
77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerPhase 3
77
Diclofenac Sodium gel, 1% + Voltaren® Gel + PlaceboPhase 3
77
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboPhase 3
77
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% + PlaceboPhase 3
77